Mubadala Bio has announced the signing of a licencing and supply agreement with Biosidus, a leading biotechnology company in Argentina, at the BIO International Convention 2026 in San Diego, US. The agreement will be executed through DiabTec, Mubadala Bio’s biologics facility in the UAE and marks an important step in the company’s efforts to expand access and availability of advanced biologic medications in the country.
The partnership is expected to support the localisation of several important biologics used in the treatment of a range of conditions across endocrinology, nephrology and oncology, reinforcing Mubadala Bio’s mission to strengthen national drug security.
Abu Dhabi has emerged as one of the few places globally where research, validation and real-world implementation happen within a single connected ecosystem. Tagged as the ‘living lab’ for life sciences, the Emirate brings together world's largest genomics programmes [FA1] [FA2] , longitudinal health data, real-world evidence, AI-enabled infrastructure and agile regulatory pathways, to make the design and delivery of care more seamless and impactful. This integrated approach is accelerating innovation that is shifting healthcare from treatment to prediction, prevention and earlier intervention.
